<i>In Vitro</i> Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
Cecília G Carvalhaes, Leonard R Duncan, Wen Wang, Hélio S. Sader
Abstract
Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates ( n = 1,211). Contezolid demonstrated potent activity against Staphylococcus aureus (MIC 50/90 , 0.5/1 mg/liter), coagulase-negative Staphylococcus (MIC 50/90 , 0.25/0.5 mg/liter), Enterococcus spp.
Topics & Concepts
Staphylococcus aureusMicrobiologyStaphylococcusPotencyEnterococcusIn vitroGramGram-positive bacteriaMicrococcaceaeBiologyAntibacterial agentLiterEnterococcus faecalisAntibacterial activityBacteriaAntibioticsBiochemistryEndocrinologyGeneticsAntimicrobial Resistance in StaphylococcusStreptococcal Infections and TreatmentsBacterial Identification and Susceptibility Testing